Can the Administration of Antithrombin III Decrease the Risk of Cerebral Hemorrhagein Premature Infants?Fulia F. · Cordaro S. · Meo P. · Gitto P. · Gitto E. · Trimarchi G. · Adelardi S. · Barberi I.
aNeonatal Intensive Care Unit, Department of Pediatrics, and bInstitute of Statistics, University of Messina, Italy
This study was carried out to determine whether the administration of antithrombin III decreases the risk of intraventricular hemorrhage in premature infants. In a randomized study, 60 infants born before 30 weeks of gestation were assigned to receive a loading dose of antithrombin III or placebo. There was no significant difference in the incidence of intraventricular hemorrhage between the antithrombin III and the placebo group (27.5 vs. 32%). Partial thromboplastin time, Quick’s prothrombin time and platelet count were also not significantly different between the 2 groups. We conclude that the administration of antithrombin III during the first 2 days of life does not decrease incidence of intraventricular hemorrhage. Antithrombin III is a very expensive therapy and its benefits should be carefully investigated before being recommended as valuable therapy.
Francesco Fulia, MD
Department of Pediatrics, ‘Barone Romeo’ Hospital
I–98066 Patti (Italy)
Tel. +39 0941 244249, E-Mail email@example.com
Number of Figures : 1, Number of Tables : 3, Number of References : 37
Biology of the Neonate (Foetal and Neonatal Research)
Vol. 83, No. 1, Year 2003 (Cover Date: Released January 2003)
Journal Editor: J.P. Relier, Paris
ISSN: 0006–3126 (print), 1421–9727 (Online)
For additional information: http://www.karger.com/bon